A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel
Latest Information Update: 04 Feb 2016
At a glance
- Drugs TAT 4 (Primary)
- Indications Nasolabial fold
- Focus Adverse reactions
- Sponsors Topokine Therapeutics
- 04 Feb 2016 New trial record